Evidence map›Paper›PMID 33408173›Full record

ArticleJournal of virology2021

Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption.

Widade Ziani, Jiasheng Shao, Xiaolei Wang, Kasi Russell-Lodrigue, Yao-Zhong Liu, Luis J Montaner, Ronald S Veazey, Huanbin Xu

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. HIV reservoirs in lymphomagenesis: hidden driver in the era of viral suppression?Microbiology and molecular biology reviews : MMBR · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Widade ZianiTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
Jiasheng ShaoTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
Xiaolei WangTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
Kasi Russell-LodrigueTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
Yao-Zhong LiuDepartment of Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
Luis J MontanerThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Ronald S VeazeyTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
Huanbin XuTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA hxu@tulane.edu.ORCID 0000-0003-1742-0979
Tulane University · USThe Wistar Institute · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6M
Towards Eradication: Reducing Proviral HIV DNA with Interferon-α ImmunotherapyU01AI110434 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J · 2014 to 2017
$7.2M
Impact of tuberculosis on the development and function of the immune system in SIV-infected infantsR01HD099857 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, WANG, XIAOLEI · 2019 to 2023
$6.9M
Novel strategies for eliminating HIV reservoirs in lymphoid tissuesR01DE025432 · NIDCR · TULANE UNIVERSITY OF LOUISIANA · PI XU, HUANBIN · 2015 to 2019
$4.0M
Development of the neonatal mucosal immune system in nonhuman primatesR01AI099795 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI WANG, XIAOLEI · 2012 to 2016
$2.9M
Pathogenesis of Neonatal SIV InfectionR01AI062410 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI VEAZEY, RONALD S. · 2004 to 2008
$2.0M
Early Immune Development and Function in Neonates Exposed to Maternal HIV InfectionR01AI147372 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI XU, HUANBIN · 2019 to 2021
$1.5M
NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI062410NIAID NIH HHS R01 AI099795NIAID NIH HHS R01 AI147372NIAID NIH HHS U01 AI110434NICHD NIH HHS R01 HD099857NIDCR NIH HHS R01 DE025432NIH HHS P51 OD011104
6 · The paper itself

Abstract

The human immunodeficiency virus (HIV) reservoir is responsible for persistent viral infection, and a small number of mosaic latent cellular reservoirs promote viral rebound upon antiretroviral therapy interruption, which is the major obstacle to a cure. However, markers that determine effective therapy and viral rebound posttreatment interruption remain unclear. In this study, we comprehensively and longitudinally tracked dynamic decay of cell-associated viral RNA/DNA in systemic and lymphoid tissues in simian immunodeficiency virus (SIV)-infected rhesus macaques on prolonged combined antiretroviral therapy (cART) and evaluated predictors of viral rebound after treatment cessation. The results showed that suppressive ART substantially reduced plasma SIV RNA, cell-associated unspliced, and multiply spliced SIV RNA to undetectable levels, yet viral DNA remained detectable in systemic tissues and lymphoid compartments throughout cART. Intriguingly, a rapid increase of integrated proviral DNA in peripheral mononuclear cells was detected once treatment was withdrawn, accompanied by the emergence of detectable plasma viral load. Notably, the increase of peripheral proviral DNA after treatment interruption correlated with the emergence and degree of viral rebound. These findings suggest that measuring total viral DNA in SIV infection may be a relatively simple surrogate marker of reservoir size and may predict viral rebound after treatment interruption and inform treatment strategies.

Indexed as

Virus ActivationAnimalsAnti-Retroviral AgentsBiomarkersCD4-Positive T-LymphocytesDNA, ViralLeukocytes, MononuclearLymph NodesMacaca mulattaProvirusesRNA, ViralSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral LoadViremiaAnti-Retroviral AgentsBiomarkersDNA, ViralRNA, Viralantiretroviral therapycell-associated virusesproviral DNAproviral DNA and viral reboundSIV/HIVviral reboundviral reservoir

Identifiers

PMID33408173
PMCPMC8094949
OpenAlexW3118783397

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.